- Experic announces capital investment from 1315 Capital to expand manufacturing and global reach.
- Funds will support international growth and enhancement of CDMO services for biopharmaceutical clients.
Experic, a US-based contract development and manufacturing organisation (CDMO), has received a substantial investment led by Philadelphia-based healthcare equity firm 1315 Capital. Existing investors, including East Seattle Partners, Harro Höfliger Packaging Systems, and Kineticos Ventures, also participated in this financing round. This capital injection aims to bolster Experic’s manufacturing capacity and enable it to expand its services internationally.
Experic’s expanded financial backing aligns with its plans to enhance its manufacturing infrastructure and advance international growth. According to Experic CEO David Wood, the support from 1315 Capital will strengthen the company’s service offerings. “This investment will empower us to continue delivering innovative solutions and white glove service that meet our clients’ needs while expanding our footprint in the global biopharma market,” Wood noted.
1315 Capital’s investment recognises the increased reliance by biopharmaceutical companies on CDMOs for specialised support in drug development and clinical trial supply. Partner Matt Reber emphasised the strategic fit, noting, “Biopharmaceutical companies are increasingly relying on specialised partners to help develop and manufacture their innovative products. Experic’s differentiated expertise, including its unique capability handling low dose powders, addresses a growing need in the market.”
Overview of outsourcing trends 
